Objective:

To explore how genomic assays have transformed decision-making for early-stage breast cancer, particularly in the context of adjuvant chemotherapy.

Key Findings:

• Genomic assays can identify patients who do not benefit from adjuvant chemotherapy.
• The MINDACT trial showed that HR+/HER2- patients with low genomic risk have excellent outcomes with endocrine therapy alone.
• Real-world evidence indicates significant chemotherapy benefits for high-risk genomic patients.
• Genomic profiling can predict responses to neoadjuvant therapies and inform surgical decisions.
• Genomic insights help personalize treatment intensity, reducing unnecessary toxicities.

Interpretation:

Genomic testing enhances treatment personalization in early-stage breast cancer, improving outcomes and minimizing overtreatment.

Limitations:

• Genomic testing may not be universally accessible or applicable to all patient populations.
• The evolving nature of genomic technologies may outpace clinical guidelines.

Conclusion:

Genomic testing is pivotal in refining treatment strategies for early-stage breast cancer, balancing efficacy with quality of life.